Kura Oncology, Inc. has entered into a collaboration and license agreement with Kyowa Kirin to develop and commercialize its product candidate ziftomenib for treating acute myeloid leukemia and other cancers, with potential payments totaling up to $1.491 billion and an upfront payment of $330 million.